TORONTO, ON / ACCESS Newswire / July 7, 2025 / The Western Investment Company of Canada Limited (TSXV:WI) (“Western“) today announced the appointment of Pablo Dancuart as Chief Financial Officer effective August 7, 2025.
Mr. Dancuart brings over fifteen years of experience in the property and casualty insurance sector and a strong track record of leading finance organizations through transformative changes, including the full implementation of IFRS 17. Prior to joining Western, Mr. Dancuart served as Vice President of Finance and Procurement at Gore Mutual Insurance Company, where he was part of the team responsible for a successful transformation of this highly respected insurer, with contributions spanning all major areas of change including the implementation of modern technology platforms, reinvention of outdated operating models, the enhancement of people strategies and the execution of high-growth, value-added initiatives.
“We are very excited to have Pablo join our team with his expertise implementing significant transformational change, including with respect to IFRS 17” said Paul Rivett, Western’s Chief Executive Officer. “We believe Pablo will be a dedicated team member and culture builder as we start Western’s new chapter as an insurance and investment holding company.”
“We would like to thank our current Chief Financial Officer, Stacey Cross, for her dedication to Western over the years and for working tirelessly to get us through our recapitalization last year. Ms. Cross will support Mr. Dancuart through this transition.” said Mr. Rivett.
As part of Mr. Dancuart’s compensation, Western has agreed to grant 1,666,666 restricted share units (RSUs) priced at $0.60 per share. Fifty percent of these RSUs will cliff vest after five years, with the balance cliff vesting after 10 years. The grant of these RSUs is subject to approval by the TSXV. It is Western’s expectation that the shares necessary to support these RSUs will be purchased in the open market and will not be issued from treasury.
About The Western Investment Company of Canada Limited
Western is an insurance and investment holding company focused on decentralized ownership of insurance businesses and centralized investment management. Western’s shares are traded on the Toronto Venture Exchange under the symbol WI.
For more information on Western, please visit its website at www.westerninvest.ca.
To add yourself to Western’s email news alert subscription please visit this link.
This news release may contain certain forward-looking information and statements, including without limitation statements pertaining to future results and plans for Western and its associated companies, acquisitions, financings and returns. Statements containing the words: ‘believes’, ‘intends’, ‘expects’, ‘plans’, ‘seeks’ and ‘anticipates’ and any other words of similar meaning are forward-looking. All statements included herein involve various risks and uncertainties because they relate to future events and circumstances beyond Western’s control.
The forward-looking statements are based on certain key expectations and assumptions made by Western, including expectations and assumptions concerning the ability of Western to successfully implement its strategic plans and initiatives.
Although Western believes that the expectations and assumptions on which the forward-looking statements made by Western are based are reasonable, undue reliance should not be placed on the forward-looking statements because no assurance can be provided that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, risks relating to regulatory compliance, risks relating to demand for the products and services provided by Fortress Insurance and other portfolio companies, risks relating to future growth prospects and business opportunities, risks that management is not able to execute its business strategy, and the impact of general economic conditions in Canada and the United States. A description of additional assumptions used to develop such forward-looking information and a description of risk factors that may cause actual results to differ materially from forward-looking information can be found in Western’s disclosure documents on the SEDAR+ website at www.sedarplus.com.
The forward-looking statements contained in this news release are made as of the date hereof and Western undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
This news release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
“Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.“
SOURCE: The Western Investment Company of Canada Limited
VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / July 7, 2025 / Mawson Finland Limited (“Mawson” or the “Company“) (TSX-V:MFL)(FRANKFURT:PM6) is pleased to announce results from remaining drillholes from the 2025 drilling season at the Company’s wholly-owned Rajapalot gold-cobalt project in Finland (see Figure 1, Table 1, Table 2, and Table 3).
Highlights:
Significant 200 m down-plunge step-out at Raja (Raja Deeps) (Figure 1, and Figure 2), including:
PAL0388b – 0.7 m @ 18.0 g/t gold (cobalt TBA)
PAL0388 – 7.9 m @ 2.29 g/t gold and 868 ppm cobalt, including:
1 m @ 8.64 g/t gold and 725 ppm cobalt
80 m strike-extension of South Palokas (South Palokas Deeps), and a 46 m down-plunge step-out at New Lens, located in the footwall-zone of the South Palokas mineralised system. Significant intercepts include:
4.2 m @ 2.46 g/t Au and 371 ppm Co (from 340.2 m), and
2.6 m @ 3.94 g/t Au and 463 ppm Co (from 399.4 m) in PAL0195.
Discovery of a new gold-only occurrence of mineralisation situated approximately 300 m west of Raja in drillhole PAL0387, assaying 0.5 m @ 14.4 g/t gold, contained within a wider 9.8 m interval lower-grade zone.
Extensive Bottom-of-till drill programme nearing completion with a total of 830 holes drilled from a planned 900 holes
Mine permitting including environmental impact assessment and zoning approvals ongoing.
Ms. Noora Ahola, Mawson Finland CEO, comments: “Our 2025 winter drilling campaign has delivered exceptional results, with significant discoveries and extensions validating Rajapalot’s exceptional growth potential across multiple zones.
The standout achievement is our 200-metre down-plunge extension at Raja Deeps, which has substantially expanded the mineralised footprint with outstanding higher-grade intercepts of 0.7 metres at 18.0 g/t gold and 7.9 metres at 2.3 g/t gold with 868 ppm cobalt – highlighted by a 1-metre interval grading 8.6 g/t gold.
We’ve also achieved an 80-metre strike extension at South Palokas Deeps and a 46-metre down-plunge step-out at New Lens in the footwall zone, with significant intercepts of 4.2 metres at 2.5 g/t gold and 371 ppm cobalt, plus 2.6 metres at 3.9 g/t gold and 463 ppm cobalt in drillhole PAL0195.
Perhaps most exciting, is our discovery of entirely new mineralisation 300 metres west of Raja, where drillhole PAL0387 intersected 0.5 metres at 14.4 g/t gold within a broader 9.8-metre mineralised zone. This breakthrough demonstrates significant exploration upside within our existing footprint.
Gold-Cobalt mineralisation has now been drilled to approximately 650 metres below surface at South Palokas and approximately 680 metres below surface at the Raja, with the mineralising system remaining open at depth across the entire project. Our comprehensive 830-hole base-of-till program is nearing completion, while we continue advancing critical mine permitting processes including environmental impact assessment and zoning approvals.”
Technical Discussion
During the 2025 winter drilling programme at Rajapalot a total of 33 drillholes of NQ diamond core, 11,397 m was drilled. To date, gold-assay results (and partial cobalt analysis) have been received for all drillholes completed in this drilling season and presented in Table 1, 2 and 3, and summarised in Figure 1.
Raja Deeps: Target-test drilling (drillhole PAL0388) of a conductive anomaly defined through DHEM geophysics, located in the down-plunge/down-dip position of the Raja projected mineralised zone (see news release dated February 11, 2025) has intercepted 7.9 m @ 2.29 g/t Au and 868 ppm cobalt from 668.3 m downhole (including a rare occurrence on visible gold as reported April 24, 2025, grading 1 m @ 8.64 g/t Au and 725 ppm Co).
Three additional ‘navi’ wedge holes were drilled from PAL0388 in order to follow up this intercept (collared between 420 and 462 m downhole), where PAL0388b returned an intercept of 0.7 m @ 18 g/t Au (cobalt TBA). Drillholes PAL0388a and PAL0388c also intercepted the mineralised horizon but returning lower-grade intercepts (refer to Table 2 and Table 3, and Figure 1 and Figure 2). Overall, these drilling intercepts represent a significant down-plunge step-out of the Raja zone, extending the known mineralised envelope of Raja by over 200 m from the previously deepest recorded intercept (refer to Figure 2).
Raja West: Target-test drilling in an area approximately 300 metres west of the Raja zone intercepted a very-shallow and broad 9.8 m thick interval of disseminated iron-sulphides, returning a gold-rich intercept of 1.5 m @ 5.47 g/t Au, including 0.5 m @ 14.4 g/t Au from only 29 m downhole (refer to Figure 1 and Figure 2). While geological interpretation of this important new intercept is still underway, this mineralised occurrence at Raja West is hosted in the immediate footwall of a north-west dipping, severely hydrothermally altered shear-zone, conforming to the geological setting of all other mineralised gold-cobalt occurrences in the Rajapalot area. As such, further exploration drilling will take place at Raja West in the upcoming 2026 drilling season, where down-dip step-out to this new mineralised zone will be tested.
New Lens/South Palokas: A total of 8 drillholes were drilled into the New Lens zone of South Palokas, of which 4 drillholes were tails/extensions drilled off existing diamond drillholes that previously ended immediately below the South Palokas zone of gold-cobalt mineralisation; some 80 to 100 m short of where New Lens lies. Of these 8 drillholes, 2 intercepted significant intercepts in New Lens; PAL0016 and PAL0195.
Drillhole PAL0195 was extended to test the down-plunge extension and continuation of the New Lens zone, where it successfully intersected multiple significant intercepts approximately 80 m down-plunge of the next nearest drillhole PAL0335. Significant intercepts recorded from PAL0195 include 4.23 m @ 2.46 g/t Au and 371 ppm Co (from 340.2 m), and 2.6 m @ 3.94 g/t Au and 463 ppm Co (from 399.35 m); refer to Figure 3 and Figure 4.
Drillhole PAL0016 was extended in order to test for lateral, northwards extension from drillhole PAL0364, where it intercepted significant mineralisation of 13.9 m @ 1.03 g/t Au and 666 ppm Co (from 291.6 m), increasing the gold-cobalt mineralised envelope of New Lens to the north by around 43 m.
Drillholes PAL0379, PAL0383, PAL0389 and PAL0393 did not intercept significant mineralisation in the New Lens zone, however, all did intercept gold-cobalt mineralisation as they passed through the South Palokas zone on their intended journey towards the New Lens target depth. PAL0383 intercepted 5.2 m @ 2.61 g/t Au and 1170 ppm Co (from 127.6 m), and 3.7 m @ 1.04 g/t Au and 758 ppm Co, from (137.45 m), representing a 18 m of mineralised step-out to the south in the upper region of the South Palokas zone. PAL0393 recorded up to 1.55 m @ 1.76 g/t Au and 168 ppm Co and 5.85 m @ 0.52 g/t Au and 224 ppm Co as it passed through the already inferred area of mineralisation in the upper-most portions of South Palokas zone supporting both grade and geological continuity as it has been modelled here.
Palokas: Drilling at deep Palokas consisted of 5 holes in total, all targeting down-dip extensions of the Palokas gold-cobalt system. Drillholes PAL0380 and PAL0386 intercepted significant mineralisation, where PAL0380 recorded multiple significant intercepts (recording a best of 6 m @ 1.03 g/t gold; as reported in previous release dated February 11, 2025), and PAL0386 intercepted a single, thinner interval of 1.05 m @ 2.26 g/t Au (cobalt results not yet received).
Drillholes PAL0377, PAL0382, PAL0386 and PAL0396 all intercepted the targeted sulfide-bearing shear structure however, the intercepted sulfidic-rich zones are not gold-bearing in these drillholes due to the interaction of the host-structure with a change in host-recks to the unfavourable dolostone rock units. Location of these Palokas drill-intercepts are illustrated in Figure 3.
Technical Background, Data Verification and Quality Assurance and Quality Control
Four diamond drill rigs from MK Core Drilling Oy, Comadev Oy and Arctic Drilling Company Oy, all with water recirculation and drill cuttings collection systems, were used in this drill program. Core diameter is NQ2 (50.7 mm). Core recoveries are excellent and average close to 100% in fresh rock. After photographing and logging in Mawson’s Rovaniemi facilities, core intervals of between 0.4 to 2 m are taken, then half-sawn by independent contractors the Geological Survey of Finland (GTK) in Rovaniemi, Palsatech Oy in Kemi and Geopool Oy in Sodankylä. The remaining half core is retained for verification and reference purposes. Analytical samples are transported by commercial transport from site to the independent contractor CRS Minlab Oy (“CRS“) facility in Kempele, Finland. Samples were prepared and analyzed for gold using the PAL1000 technique which involves grinding the sample in steel pots with abrasive media in the presence of cyanide, followed by measuring the gold in solution with flame AAS equipment. Samples for multi-element analysis (including cobalt) are pulped at CRS, then transported by air to MSALABS in Vancouver, Canada and analyzed using four acid digest ICP-MS methods. All the foregoing laboratories are independent of the Company. The quality assurance and quality control program of Mawson consists of the systematic insertion of certified standards of known gold content, duplicate samples by quartering the core, and blanks placed within sample runs in interpreted mineralized rock. In addition, CRS inserts blanks and standards into the analytical process. In addition to the sample preparation and security measures described above, data verification procedures are well integrated into the Company’s quality assurance and quality control program. Routine ongoing checking of all data is undertaken prior to being uploaded to the database. This will be followed by independent data verification audits at exploration milestones throughout the Rajapalot project’s development. Dr. Fromhold (see “Qualified Person” below) has also reviewed the qualifications and analytical procedures of the above-mentioned laboratories, photographs of drill cores, and the PEA in connection with verifying the exploration information presented herein.
Of the 33 drillholes drilled, 3 holes were abandoned due to excessive and unexpected deviation leaving 30 drillholes drilled to target/completion. Additionally, a further 5 drillholes were tails/continuations of existing and older drillholes, while 3 drillholes were ‘navi’ or directional holes collared beneath the surface from an existing deep drillhole.
All maps have been created within the KKJ3/Finland Uniform Coordinate System (EPSG:2393). Tables 1-3 provide collar and assay data. Due to the typically low angles of drill intercepts, the true thickness of the mineralized intervals are interpreted to be approximately 80-90% of the drilled thickness. Table 3 gives detailed individual assay data of all intervals reported in this press release. Intersections are reported with a lower cut of 0.3 g/t Au over 1 m sampled intervals, with composite data (Table 2) containing no more than 2 m of consecutively sampled waste-rock (i.e., 2 m @ <0>
Deposit Model
At Rajapalot, mineralization is regarded as orogenic in nature. All examples of gold-cobalt mineralisation are consistently located within highly-sheared and foliated wall-rocks adjacent to strongly hydrothermally altered, northwest to north dipping shear-zones. Mineralisation is typically encountered as disseminated to semi-massive sulfide lenses (predominantly pyrrhotite and lesser pyrite ± cobaltite), hosted within strongly deformed and altered, mafic volcanic and volcaniclasitic stratigraphy of the upper portions of the Paleoproterozoic-aged Kivalo Group of the Peräpohja Greenstone Belt. Prospects with high-grade gold and cobalt mineralisation at Rajapalot occur across a 3 km (east-west) by 2 km (north-south) area within the larger Rajapalot project area measuring 4 km by 4 km with multiple mineralized boulders, base-of-till (BOT). Gold-Cobalt mineralization at Rajapalot has been drilled to approximately 650 metres below surface at both South Palokas and Raja prospects, with mineralisation remaining open at depth across the project.
Rajapalot Mineral Resource
An Inferred Mineral Resource (“MRE”) has been calculated for the Rajaplot project (effective date August 26, 2021), and is based on an ‘underground only’ mining scenario containing 9.8 million tonnes @ 2.8 g/t gold (“Au”) and 441 ppm Co, equating to 867 thousand ounces (“koz”) gold and 4,311 tonnes of cobalt.
Zone
Cut-off
(AuEq¹)
Tonnes
(kt)
Au
(g/t)
Co
(ppm)
Au
(koz)
Co
(tonnes)
Palokas
1.1
5,612
2.8
475
501
2,664
Raja
1.1
2,702
3.1
385
271
1,040
East Joki
1.1
299
4.5
363
43
109
Hut
1.1
831
1.3
428
36
355
Rumajärvi
1.1
336
1.4
424
15
142
Total Inferred Resources
9,780
2.8
441
867
4,311
Rajapalot Inferred Mineral Resource Effective August 26, 2021
The independent geologist and Qualified Person as defined in NI 43-101 for the mineral resource estimates is Mr. Ove Klavér (EurGeol). The effective date of the MRE remains unchanged to the Previous MRE (August 26, 2021, available on SEDAR as filed by the previous owner, Mawson), and will be restated in the PEA technical report when it is filed.
The mineral estimate is reported for a potential underground only scenario. Inferred resources were reported at a cut-off grade of 1.1 g/t (AuEq1 Au g/t + Co ppm /1005) with a depth of 20 meters below the base of solid rock regarded as the near-surface limit of potential mining.
Wireframe models were generated using gold and cobalt shells separately. Forty-eight separate gold and cobalt wireframes were constructed in Leapfrog Geo and grade distributions independently estimated using Ordinary Kriging in Leapfrog Edge. A gold top cut of 50 g/t Au was used for the gold domains. A cobalt top cut was not applied.
A parent block size of 12 m x 12 m x 4 m (>20% of the drillhole spacing) was determined as suitable. Sub-blocking down to 4 m x 4 m x 0.5 m was used for geologic control on volumes, thinner and moderately dipping wireframes.
Rounding of grades and tonnes may introduce apparent errors in averages and contained metals.
Drilling results to 20 June 2021.
Mineral Resources are not Mineral Reserves and do not have demonstrated economic viability.
Qualified Person
The technical and scientific information in this news release was reviewed, verified and approved by Dr. Thomas Fromhold, an employee of Fromhold Geoconsult AB, and Member of The Australian Institute of Geosciences (MAIG, Membership No. 8838). Dr. Fromhold is a “qualified person” as defined under NI 43-101. Dr. Fromhold is not considered independent of the Company under NI 43-101 as he is a consultant of the Company.
About Mawson Finland Limited
Mawson Finland Limited is an exploration stage mining development company engaged in the acquisition and exploration of precious and base metal properties in Finland. The Company is primarily focused on gold and cobalt. The Corporation currently holds a 100% interest in the Rajapalot Gold-Cobalt Project located in Finland. The Rajapalot Project represents approximately 5% of the 100-square kilometres Rompas-Rajapalot Property, which is wholly owned by Mawson and consists of 13 granted exploration permits for 11,262 hectares. In Finland, all operations are carried out through the Company’s fully owned subsidiary, Mawson Oy. Mawson maintains an active local presence of Finnish staff with close ties to the communities of Rajapalot.
Additional disclosure including the Company’s financial statements, technical reports, news releases and other information can be obtained at mawsonfinland.com or on SEDAR+ at www.sedarplus.ca.
Media and Investor Relations Inquiries
Please contact: Neil MacRae Executive Chairman at neil@mawsonfinland.com or +1 (778) 999-4653, or Noora Ahola Chief Executive Officer at nahola@mawson.fi or +358 (505) 213-515.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. No securities regulatory authority has reviewed or approved of the contents of this news release.
Forward-looking Information
This news release includes certain “forward-looking information” and “forward-looking statements” within the meaning of applicable securities laws (collectively, “forward-looking information”) which are not comprised of historical facts. Forward-looking information includes, without limitation, estimates and statements that describe the Company’s future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Forward-looking information may be identified by such terms as “believes”, “anticipates”, “expects”, “estimates”, “aims”, “may”, “could”, “would”, “will”, “must” or “plan”. Since forward-looking information is based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to the Company, and management of the Company believes them to be reasonable based upon, among other information, the contents of the PEA and the exploration information disclosed in this news release, the Company provides no assurance that actual results will meet management’s expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward-looking information in this news release includes, but is not limited to, the Company’s objectives, goals or future plans, any expected receipt of additional assay results or other exploration results and the impact upon the Company thereof, any expected milestone independent data verification, the continuance of the Company’s quality assurance and quality control program, potential mineralization whether peripheral to the existing Rajapalot resource or elsewhere, any anticipated disclosure of assay or other exploration results and the timing thereof, the estimation of mineral resources, exploration and mine development plans, including drilling, soil sampling, geophysical and geochemical work, any expected search for additional exploration targets and any results of such searches, potential acquisition by the Company of any property, the growth potential of the Rajapalot resource, all values, estimates and expectations drawn from or based upon the PEA, and estimates of market conditions. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to: any change in industry or wider economic conditions which could cause the Company to adjust or cancel entirely its exploration plans, failure to identify mineral resources or any additional exploration targets, failure to convert estimated mineral resources to reserves, any failure to receive the results of completed assays or other exploration work, poor exploration results, the inability to complete a feasibility study which recommends a production decision, the preliminary and uncertain nature of the PEA, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, environmental or other project approvals, political risks, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, changes in exchange rates, fluctuations in commodity prices, delays in the development of projects, capital and operating costs varying significantly from estimates and the other risks involved in the mineral exploration and development industry, and those risks set out in the Company’s public documents filed on SEDAR+. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.
Figure 1: Locality Plan view map illustrating collar positions and drill-hole traces from Mawson’s 2025 winter drilling campaign as drilled to time of writing; inset box illustrates location of Figure 2, while green lines represent section lines of Figure 3 and Figure 4.
Figure 2: Plan view illustration of the Raja system displaying intercepts from 2025, as highlighted with drillhole numbers in bold. Red arrows indicate the direction where gold-cobalt mineralisation remains untested and open.
Figure 3: Long-section illustration of the Palokas and South Palokas zones (left) and New Lens zone as located in the footwall of South Palokas (right) as projected onto the same panel. Intercepts from 2025 are highlighted with drillhole numbers in bold. Red dashed line represents the projection of the South Palokas cross-section as presented in Figure 4 (location of section lines illustrated in Figure 1; A and A’). Red arrows indicate the direction where gold-cobalt mineralisation remains untested and open.
Figure 4: Cross-section of the South Palokas and New Lens (South Palokas footwall) zones of mineralisation. Drillholes from 2025 are presented as black bold lines, and results in bold red text. The location and projection of this cross-section is illustrated on the long section in Figure 3 with a dashed red-line (location of section line illustrated in Figure 1; B and B’).
Table 1: Drillhole collar locations presented within (finish KKJ grid), with corresponding hole orientations (azimuth and dip measured in degrees), total depth, and prospect target. Results from drillholes in regular text are presented within, holes in italics have previously been published.
Hole ID
Easting KKJ
Northing KKJ
Elevation (mRL)
Azimuth
Dip
Total Depth
Prospect
PAL0016ext
3408333.32
7373665.92
173.81
113.2
-58.1
329.5 (260.5)
South Palokas
PAL0122ext
3408353.99
7373580.12
175.04
117.2
-60.0
299.2 (209.6)
South Palokas
PAL0180ext
3408127.24
7372705.59
174.00
41.0
-61.4
812 (778.65)
Raja
PAL0195ext
3408354.19
7373579.82
175.05
62.6
-78.0
447.6 (254.6)
South Palokas
PAL0204ext
3408521.78
7373603.97
173.39
234.8
-85.0
287.8 (149.2)
South Palokas
PAL0373
3407806.74
7374005.83
171.99
127.6
-61.2
1004.0
South Palokas
PAL0374
3408899.96
7372383.28
172.44
69.1
-75.2
300.0
Raja
PAL0375
3409137.40
7374399.43
176.69
186.1
-44.8
400.8
Hirvimaa
PAL0376
3408941.23
7372298.28
173.19
148.0
-63.2
167.6
Raja
PAL0377
3408276.44
7374025.77
174.28
84.8
-65.1
551.5
Palokas
PAL0378
3408816.57
7372713.16
174.45
183.1
-61.0
376.4
Raja
PAL0379
3408499.30
7373520.30
174.18
130.1
-50.2
191.2
South Palokas
PAL0380
3408275.85
7374025.30
174.20
101.1
-69.0
568.2
Palokas
PAL0381
3408816.79
7372713.47
174.39
170.0
-67.0
380.0
Raja
PAL0382
3408335.65
7373897.76
173.97
100.1
63.1
484.5
Palokas
PAL0383
3408347.47
7373503.87
173.69
75.2
-73.0
404.0
South Palokas
PAL0384
3408065.71
7373970.95
172.17
126.1
-79.9
809.6
South Palokas
PAL0385
3409025.94
7372287.86
170.06
290.0
-73.0
209.1
Raja
PAL0386
3408275.45
7374025.31
174.13
100.0
-77.3
638.3
Palokas
PAL0387
3408552.29
7372181.02
173.68
154.7
-45.1
73.0
Raja
PAL0388
3408237.23
7372831.33
182.18
50.6
-73.3
743.2
Raja
PAL0388A
3408237.23
7372831.33
182.18
50.6
-75.3
722.5
Raja
PAL0388B
3408237.23
7372831.33
182.18
50.6
-75.3
703.5
Raja
PAL0388C
3408237.23
7372831.33
182.18
50.6
-75.3
716.1
Raja
PAL0389
3408402.41
7373549.59
174.54
137.0
-45.1
217.7
South Palokas
PAL0390
3408086.94
7373644.48
172.81
45.0
-79.5
230.5
Hole Abandoned
PAL0391
3408238.79
7372832.20
181.87
56.0
-73.1
31.4
Hole Abandoned
PAL0392
3408274.84
7374024.71
174.05
114.0
-70.3
589.8
Palokas
PAL0393
3408402.75
7373550.19
174.34
124.9
-53.1
265.7
South Palokas
PAL0394
3408086.84
7373644.42
172.81
45.0
-83.0
84.7
Hole Abandoned
PAL0395
3408086.10
7373643.95
172.74
35.0
-83.0
680.6
South Palokas
PAL0396
3407872.38
7373234.12
173.36
129.8
-66.0
368.9
Hut
PAL0397
3407526.02
7372693.61
174.16
184.9
-44.9
260.0
Rumajarvi
Table 2: Composited gold and cobalt concentrations from the drillholes reported in this news release. Individual assay values are listed in Table 3 hereinbelow.
Hole ID
From
To
Thickness (m)1
Gold (g/t)
Gold (gram-m)
Cobalt ppm
PAL0016ext
291.60
305.50
13.90
1.03
14.32
666.1
PAL0195ext
340.20
344.43
4.23
2.46
10.39
370.5
PAL0195ext
347.50
348.25
0.75
0.45
0.33
340.4
PAL0195ext
357.35
358.15
0.80
0.42
0.34
579.4
PAL0195ext
362.00
363.00
1.00
0.30
0.30
673.3
PAL0195ext
391.10
393.25
2.15
0.34
0.74
719.1
PAL0195ext
399.35
401.95
2.60
3.94
10.25
462.8
PAL0379
5.60
11.80
6.20
1.17
7.23
268.3
PAL0381
202.20
203.00
0.80
0.42
0.34
TBA
PAL0381
210.60
212.35
1.75
0.92
1.61
TBA
PAL0383
83.85
84.85
1.00
0.90
0.90
116.6
PAL0383
90.75
91.75
1.00
0.69
0.69
76.4
PAL0383
105.00
111.60
5.00
0.49
3.21
227.8
PAL0383
127.60
132.80
5.20
2.61
13.60
1169.7
PAL0383
138.05
141.15
3.10
1.19
3.69
877.7
PAL0383
148.70
152.65
3.95
0.40
1.57
116.0
PAL0384
588.00
588.85
0.85
0.41
0.35
TBA
PAL0386
462.00
463.05
1.05
2.26
2.37
TBA
PAL0387
29.50
31.00
1.50
5.47
8.20
30.9
PAL0388
42.60
43.60
1.00
1.45
1.45
269.5
PAL0388
668.30
676.20
7.90
2.29
18.05
868.6
PAL0388
684.10
689.10
5.00
0.90
4.52
232.5
PAL0388A
690.90
692.30
1.40
0.96
1.34
1169.6
PAL0388B
688.20
688.90
0.70
18.00
12.60
TBA
PAL0388C
683.00
686.35
3.35
0.64
2.14
TBA
PAL0388C
694.45
696.65
2.20
0.72
1.57
TBA
PAL0388C
698.63
701.00
2.37
0.49
1.15
TBA
PAL0389
60.50
62.05
1.55
1.36
2.10
TBA
PAL0389
66.70
68.55
1.85
0.90
1.67
TBA
PAL0389
82.30
82.95
0.65
0.54
0.35
TBA
PAL0393
66.90
68.45
1.55
1.76
2.72
167.9
PAL0393
94.15
100.00
5.85
0.52
3.07
224.1
PAL0395
523.75
529.20
5.45
1.53
8.32
TBA
PAL0395
541.35
542.90
1.55
0.83
1.28
TBA
PAL0395
549.70
555.55
5.85
1.40
8.20
TBA
PAL0395
610.75
611.50
0.75
0.72
0.54
TBA
1True-thickness of the mineralized intervals are interpreted to be approximately 80-90% of the Drilled Thickness. True-thickness is not precisely known at this time.
Table 3: All gold sample intervals with their corresponding gold and cobalt concentrations (where available), that are contained within above composited intervals, that meet the lower-cut criteria of 1 m intervals at greater than 0.3 g/t gold, containing no more than 2 m of internal waste (i.e., 2 consecutive m intervals containing samples grading <0>
New and Unprecedented Survival, Respiratory, and Biomarker Data Prove that NurOwn Helps People with ALS Live Longer and Live Stronger
BREMERTON, WA / ACCESS Newswire / July 7, 2025 / On July 4, 1939, Lou Gehrig delivered his iconic “luckiest man” speech, announcing his retirement from the New York Yankees. On that day, ALS ended his Hall of Fame career. Less than two years later, ALS ended his life at just 37 years old.
In the last 86 years, the lethal outcome has not changed. ALS is a cruel, paralyzing and 100% fatal disease. But today, the ALS community has hope. A coalition of ALS patients and family members has filed a Citizens’ Petition with the FDA, requesting the approval of NurOwn, a neurotrophically-enhanced stem cell therapy.
Backed by a decade of real-world data from the NurOwn trials and Expanded Access Program (EAP), the 309-page Citizens’ Petition details the unprecedented survival, respiratory, and biomarker data for the FDA’s consideration. The new evidence is supported by testimony from top ALS neurologists who were the trial’s principal investigators, and the “totality of the evidence” from the Phase 3 trial. And, it aligns with real-world evidence where trial participants (now-unblinded) and their treating neurologists have proclaimed that NurOwn improves how people with ALS “feel, function and survive.”
NurOwn: A Revolutionary Approach to ALS Treatment
Developed by BrainStorm Cell Therapeutics, NurOwn combines the restorative potential of autologous mesenchymal stem cells with the regenerative power of neurotrophic factors, which are like “Miracle-Gro” for dying motor neurons. NurOwn uses a patient’s own stem cells that work like a FedEx truck, delivering nano-packages of neurotrophic factors and immunomodulatory cytokines directly to damaged motor neurons.
The results are profound. Within days, trial participants reported halting of symptoms like fasciculations, cramping and clonus; and some improvements in function. With additional doses, the EAP data confirm NurOwn’s ability to slow lethal ALS progression, improve function, restore breathing, and extend survival – offering a lifeline to those battling this 100% fatal and paralyzing disease.
Unprecedented Survival and Respiratory Data
Survival data have long been the gold standard for FDA approvals; and as Commissioner Makary has emphasized: “gold standard science and common sense” will guide this FDA’s decisions. To that end, Petitioners have submitted survival data derived from their own real-world evidence over the past decade. These survival data are unprecedented in ALS clinical trial history.
Five-Year Survival: 100% in NurOwn EAP vs. 20% in ALS natural history. All EAP participants (n=10) achieved five-year survival without tracheostomies.
Extended Tracheostomy-Free Survival (TFS): 7-year median tracheostomy-free survival (range from 5 to 8.5 years), far surpassing the 2.5- to 3-year median in ALS natural history data.
Progression-Free Survival (PFS): When patients received NurOwn, they experienced PFS ranging from a few months up to 17 months.
(See Petition’s Emergent Fact section C at pg 19-33).
At the FDA Advisory Committee meeting for NurOwn in 2023, Dr. Anthony Windebank of Mayo presented the clinical trial data and shared his expert opinion about the progression-free survival that he and other experienced trial investigators had witnessed – unprecedented in their prolific 40+ year neurology practices:
“I think this data is compelling & it should be approved…. While not everyone responds to the treatment, there are clearly a significant number who do. I have clearly seen some people stabilize in a way that I have never seen in any other trial. In fact, in the small number of people who participated in EAP and received 6-9 treatments, there were people who stabilized while on NurOwn in the trial. In the interval before they were in the EAP – which was over a year or more in some cases – these participants deteriorated, then again stabilized in the additional [EAP] treatment period. There were some who IMPROVED their score. Other investigators who have been working ‘hands on’ with the participants in the trial have seen similar responses….”
Dr. Windebank’s testimony underscores the unprecedented impact of NurOwn on people with ALS. And the NurOwn survival data is buttressed by other compelling efficacy data also detailed in the Citizen’s Petition:
Long-term Preservation of Respiratory Function: A 5- to 8-year delay in the need for non-invasive ventilation (NIV) over a 15-month natural history; and significant stabilization or improvement in Forced Vital Capacity (FVC), both key predictors of ALS survival. (See Emergent Fact section D at pg 34-44).
Long-term Slowing of ALS Progression: Up to an 85% slowing in ALS progression rate, from a trial qualification of a minimum loss of 1 point per month to 0.15 points per month after receiving NurOwn. (See Emergent Fact section F at pg 44-46).
Biomarker Evidence: 23 CSF biomarkers demonstrate statistically significant changes and NurOwn’s target engagement across pathways of neuroprotection, neuroinflammation, and neurodegeneration. (See Fact section M at pgs 156-166).
Real-World Evidence and Patient Experiences
Our Citizens’ Petition also leverages real-world evidence (RWE) and real-world data (RWD) from the EAP and Right to Try – consistent with the Congressional intent of the 21st Century Cures Act. Multiple trial participants testified, submitted Public Comments and shared their RWE, which aligns with the type of efficacy evidence specified in the ALS Guidance Document and 21st Century Cures.
At the time of the advisory committee meeting in 2023, many trial participants reported tangible improvements in how they felt and functioned, and hence, an improved quality of life. (See sections H & I, pgs. 91-127). Their testimony was supported by video evidence documenting those improvements and by the opinions from multiple treating neurologists outside the clinical trial. For example, neuromuscular specialist Dr. Danielle Geraldi-Samara submitted a Public Comment to the FDA about what she observed in many of her patients participating in the NurOwn Phase 3 trial and EAP:
“The real world evidence could not be more striking. I have known patients nearly immobile who gained some functionality in their gait, patients with severe dysarthria become intelligible, patients who could not manage the fine motor skill needed to button or zipper, finally able to dress independently. I have patients with solid plateaus [in ALSFRS-R scores] over the course of a year.”
Her clinical observations of progression-free survival after the NurOwn trial mirror those of Dr. Windebank and the other investigators during the trial and EAP. Now that the Phase 3 trial has been unblinded, multiple trial participants have confirmation that NurOwn halted their lethal progression and helped some people regain function. Our lived patient experiences now have both validation and vindication. When people are becoming paralyzed, it’s common sense that we know when a therapy helps us function. Our lived patient experiences aren’t anecdotal hyperbole; they are evidence.
And as Commissioner Makary recently said at the Gene and Cell Therapy Forum, there is value in learning from “n of 1” cases. Combined, the EAP “n of 10” and the right to try “n of 1” illustrate compelling and consistent, dose-dependent evidence of efficacy.
Reinforcing the efficacy data, Navy pilot Matt Bellina shared the RWE and RWD contained in his VA medical records in hisblog and onsocial media. Matt too experienced unprecedented clinically meaningful improvements after receiving 7 doses of NurOwn via Right to Try. Although he was a slow progressor, diagnosed in 2011, Matt’s ALS had progressed significantly. He was choking on food, using NIV to breathe at night; had little use of his hands; and could not stand without assistance. His data are informative, supporting evidence of efficacy because he is the only person in the US who received 6 consecutive doses; because he was the only “slow progressor” to receive NurOwn; and because his baseline score was 21/48 on the ALS Functional rating scale.
Matt’s large magnitude, dose-dependent improvement in function was immediate and obvious. (See section J at pgs 128-133). Matt has video documenting him standing out of a wheelchair unassisted – the first time in two years. He stopped choking on food. He improved his functional score by 6 points. His FVC stabilized and he stopped using NIV to breathe for more than 4 years. NurOwn interrupted Matt’s lethal trajectory to death.
Totality of Evidence Methodology for Rare Diseases
To determine if a therapy can meet the approval threshold of “substantial evidence,” the FDA asks if a therapy improves how people “feel, function or survive.” Regulators look principally at the trial’s primary endpoint at one fixed point in time at the end of the trial. But in heterogeneous rare diseases with small populations and short placebo-controlled trials, efficacy signals can be missed. Hence, it’s much more likely to result in a Type II statistical error: delaying or denying approval of a drug that does work. In a terminal disease like ALS, Type II errors cause ongoing paralysis and death.
Thus, the Citizens’ Petition reasserts the propriety of the FDA’s use of the “totality of evidence” statistical methodology to assess NurOwn’s efficacy. This approach – widely accepted in oncology for evaluating therapies in heterogeneous, rare populations – strengthens the case for NurOwn’s approval by highlighting the consistent benefits in the subgroup of ALS patients earlier in ALS progression (akin to a drug working on stage I and II cancer patients).
When including the trial population with the most advanced ALS (akin to stage III/IV cancer), the trial did not meet its endpoints. But when looking at the patients earlier in ALS progression, NurOwn met statistical significance. Using the “totality of the evidence” methodology, renowned biostatistician and Wilkes Award winner, Dr. Lee-Jen Wei of Harvard / Dana Farber analyzed the multiple trial endpoints, across multiple functional scale domains, at multiple time points throughout the 28-week trial. He testified at the Advisory Committee meeting that these p-values were: 0.045, 0.021, 0.007 and 0.005; thus providing more supporting evidence of NurOwn’s efficacy.
Meeting FDA Approval Thresholds
The Citizens’ Petition asserts that NurOwn achieves the statutory thresholds for multiple FDA approval pathways:
1. Traditional Approval NurOwn’s survival data, including the five-year survival, TFS, PFS and OS, meet the “substantial evidence” threshold of one well-controlled trial plus supporting evidence. This conclusion aligns with the FDA’s recognition that survival data are the gold standard in FDA approvals. Thus the diversity and magnitude of NurOwn’s survival outcomes fulfills both the “quality” and “quantity” requirements of “substantial evidence.” (See Emergent Fact section C, pgs. 19-33).
2. Accelerated Approval NurOwn meets the “reasonable likelihood” threshold for accelerated approval. The survival data from the “n of 10” EAP are “reasonably likely to predict” a favorable impact on irreversible mortality of the 32,000 people with ALS. This survival data far surpasses survival data supporting the accelerated approval of many cancer therapies. (See comparison at Memorandum section I, pgs. 191-209 and Exs. A & B).
NurOwn’s respiratory data, including delays in time-to-tracheostomy, time-to-NIV, and improved FVC, are also reasonably likely to predict a favorable impact on mortality. (See Emergent Fact section D, pgs. 34-43 and Memorandum II.C pgs. 219-222).
NurOwn’s CSF biomarker data are also reasonably likely to predict a “clinically meaningful” effect. NurOwn caused statistically significant changes in first-in-class CSF biomarkers – regardless of disease severity and only in the NurOwn treatment arm. Of the 45 pre-specified biomarkers tested, 23 had statistically significant changes and 15/23 had p-values ≤0.001. These CSF biomarkers provide objective biological evidence of target engagement across pathways of neuroinflammation, neurodegeneration, and neuroprotection. (See Petition Facts section M, pgs. 156-166 and Memorandum section II.C pgs. 219-222).
Additionally, Brainstorm Cell has shared neurofilament light biomarker data in a poster presentation at the 2024 NEALS conference. As the FDA has acknowledged, as ALS progression advances, harmful NfL increases, reflecting more diseased and dying motor neurons. At the end of the Phase 3 trial, there was a 9.4% delta between the NurOwn and placebo arm (p=.037).
But in those 10 from EAP who were earlier in progression at the start of the Phase 3 trial, the delta between the NurOwn and placebo arms was more apparent. At the end of Phase 3, the 4/10 on placebo had a 37% increase in harmful NfL whereas the 6/10 on NurOwn had a 4% decrease in NfL. With the additional dosing in EAP, the 4/10 in the placebo-crossover group finally experienced a 5% decline in harmful NfL, whereas people on NurOwn maintained a 36% decrease from baseline. Not surprisingly, those who received the most doses of NurOwn and received it earliest in ALS progression had the largest magnitude functional changes and as well as the largest decrease in NfL levels – with two people who received 9 total doses having a decrease of ≥60% in harmful NfL levels. (See table in section II.C.2.a on page 222).
As such, the changes in CSF biomarkers are reasonably likely to predict a clinically meaningful benefit, and thus, the third way that NurOwn can meet the threshold for accelerated approval.
3. Conditional Approval NurOwn aligns with Commissioner Makary’s proposed “plausible mechanism of action” threshold for conditional approval. Both stem cell technology and neurotrophic factors are plausible mechanisms of action in ALS; and NurOwn’s CSF biomarker data confirms biological plausibility. (See Petition Fact section N, pgs. 173-176 and Memorandum section II.G at pgs. 234-241).
A Call for De Novo Review and Expedited Action
The Citizens’ Petition requests a de novo review by the FDA. The Center for Biologics Evaluation and Research (CBER) has not ever considered the EAP survival, respiratory, or biomarker data, nor has it considered the Right to Try data from Navy pilot Matt Bellina, nor the unblinded and now corroborated RWE/RWD from people who have benefitted from NurOwn since 2011. The Petitioners also request that CBER use the Commissioner’s new Priority Voucher to expedite review. The Citizens’ Petition also proposes that FDA consider the far-reaching benefits of a Phase 4 post-marketing study, including a biorepository and natural history/exposome database, which aligns with the FDA Priorities outlined by Doctors Makary and Prasad.
A Historic Moment for the ALS Community
At the recent 2025 Gene and Cell Therapy Forum, Secretary Kennedy shared that the FDA will do everything it can to “accelerate approvals for rare diseases.” And in their Joint OpEd for JAMA Viewpoints, Commissioner Makary and Director Prasad said the FDA is committed to “rapidly usher to market new products with transformational potential.” In furtherance of that commitment, Director Prasad told the rare disease community that the FDA will:
“approve anything that is an incremental advancement”
accelerate therapies by “taking action at the first sign of promise for rare diseases” and at the “earliest sign of statistical evidence”
monitor people post-market to “ensure people live longer, stronger.”
The Citizens’ Petition argues that NurOwn has more than transformational potential. Rather, the survival and respiratory data, along with 8 years of RWE, demonstrate its already transformational impact on people living with ALS. Thus, the ALS community calls on the FDA to approve NurOwn, honoring its commitment to marry “gold standard science and common sense.”
ALS is stealing decades from our lifespans. Just as the FDA acts with urgency for people with terminal cancer, the Citizens’ Petition asks the FDA to act with the same urgency as ALS is killing our motor neurons. Please don’t let another generation of people with ALS die waiting when we know a stem cell therapy can help us live.
About ALS ALS is a 100% fatal, heterogeneous, rare neurodegenerative disease. As motor neurons die, the brain can no longer communicate with the voluntary muscles, which slowly become paralyzed. For reasons researchers don’t fully understand, ALS impacts only the motor neurons, not the sensory neurons. Thus, people with ALS still feel cramping, sensations, fasciculations and pain, but they can’t move to respond to them. Ultimately, people lose the ability to walk, talk, move, eat, drink, swallow, and eventually, breathe.
About the Petitioners
The Petitioners are a coalition of people who received NurOwn and others with ALS who could not. We are committed to advancing research, treatment access, and policy changes for ALS.
With Australian investor activity on the rise, Liberty offers investment home loans to help borrowers realise their property potential.
MELBOURNE, AU / ACCESS Newswire / July 6, 2025 / New data from PropTrack reveals a steady increase in new loans for investors across Australia over the past 18 months.
As investor activity grows, leading lender Liberty says flexible investment home loans could help borrowers capitalise on current market opportunities.
Communications Manager, Bernadine Pantarotto, says those looking to start or grow their property portfolio could benefit from the non-bank’s free-thinking solutions.
“For borrowers on their property journey, an investment home loan could be a smart move to help enter the market, build equity and generate rental income,” says Ms Pantarotto. Liberty offers flexible property investment solutions to support a variety of customers, including those new to the lending process.
“From first-time buyers to seasoned investors, our investment home loans are designed to help borrowers achieve their property goals,” says Ms Pantarotto.
With a proud history of supporting customers to access free-thinking home loan options, Liberty strives to provide solutions tailored to the needs of each individual customer.
Unlike traditional lenders, Liberty takes a holistic approach to lending, combining risk-based assessment with personalised service to support more customers.
“We understand no two borrowers are the same, which is why we look beyond just the numbers to assess a customer’s financial circumstances,” says Ms Pantarotto.
“Whether a borrower is self-employed or working with a smaller deposit, we have flexible solutions to help keep their investment property plans moving forward,” says Ms Pantarotto.
Liberty offers free-thinking options including low doc and low deposit investment home loans to support borrowers to unlock their property potential.
Beyond investment loans, Liberty has solutions across owner-occupied home loans, as well as personal, car, business, commercial and SMSF loans.
With close to 30 years of experience, Liberty continues to help more people say ‘yes’ to their plans.
“We have proudly supported over 900,000 customers with our free-thinking solutions and remain committed to helping more people get and stay financial,” says Ms Pantarotto.
About Liberty As one of Australia’s leading non-bank lenders, Liberty offers innovative solutions to support customers with greater choice. Over more than 27 years, this free-thinking approach to loan solutions has seen more than 900,000 customers across a wide range of home, car, business and personal loans, as well as SMSF lending and insurance. Liberty remains the only non-bank lender with an investment-grade credit rating offering custom and prime solutions to help more people get financial.
Approved applicants only. Lending criteria apply. Fees and charges are payable. Liberty Financial Pty Ltd ACN 077 248 983 and Secure Funding Pty Ltd ABN 25 081 982 872 Australian Credit Licence 388133, together trading as Liberty Financial.
Clear Start Tax clarifies why some states still require Form 1095-A, even though the federal health coverage penalty was eliminated.
IRVINE, CA / ACCESS Newswire / July 4, 2025 / Despite the federal penalty being eliminated, many taxpayers are still receiving health insurance forms, leaving them unsure whether action is required. Clear Start Tax is warning filers not to ignore Form 1095-A, especially in states that still enforce their own coverage mandates.
“The IRS eliminated the federal individual mandate penalty in 2019, but that doesn’t mean everyone is off the hook,” said the Head of Client Solutions at Clear Start Tax. “Several states still require proof of coverage, and skipping Form 1095-A or other related forms can delay your return – or worse, result in state fines.”
Why You May Still Receive Form 1095-A
Many taxpayers think the form is irrelevant now that the ACA penalty is gone. But Clear Start Tax explains that Form 1095-A is still issued if you enrolled in a Marketplace health plan, and it plays a key role in reconciling any premium tax credits you received. It’s also used to reconcile the advance premium tax credits you received with what you actually qualified for, based on your reported income.
If the numbers don’t match what the IRS or your state expects, your refund could be delayed or adjusted.
States That Still Enforce Health Insurance Penalties
Even though the federal penalty is gone, a growing number of states have their own health coverage mandates – and their own penalties. As of 2025, these states still impose a fine if you go without qualifying coverage and don’t qualify for an exemption:
California
Massachusetts
New Jersey
Rhode Island
Vermont (reporting only)
Washington, D.C.
These states often require taxpayers to file specific health coverage forms along with their state return, and missing or inaccurate documentation can trigger state-level penalties.
What to Do If You’re Uninsured or Received a Marketplace Form
Clear Start Tax advises taxpayers to take the following steps to avoid penalties or processing delays:
Don’t ignore Form 1095-A – include it with your return if applicable.
Check your state’s requirements if you live in one that enforces coverage mandates during the tax year.
Make sure your premium tax credits were reconciled properly to avoid refund issues.
File all required health coverage documentation, especially in California, where the Franchise Tax Board tracks non-compliance aggressively.
“Many people are caught off guard because they assume health insurance is no longer part of tax season,” said the Head of Client Solutions. “But in states with mandates, missing documentation can still cost you money.”
Behind on Taxes or Hit With a Penalty? Relief May Be Available
Health-related penalties can overlap with broader tax issues, including unfiled returns, missed income, or existing IRS debt. Clear Start Tax helps individuals nationwide resolve complex tax situations and determine eligibility for the IRS Fresh Start Program.
By answering a few simple questions, taxpayers can find out if they’re eligible for the IRS Fresh Start Program and take the first step toward resolving their tax debt.
About Clear Start Tax
Clear Start Tax is a full-service tax liability resolution firm that serves taxpayers throughout the United States. The company specializes in assisting individuals and businesses with a wide range of IRS and state tax issues, including back taxes, wage garnishment relief, IRS appeals, and offers in compromise. Clear Start Tax helps taxpayers apply for the IRS Fresh Start Program, providing expert guidance in tax resolution. Fully accredited and A+ rated by the Better Business Bureau, the firm’s unique approach and commitment to long-term client success distinguish it as a leader in the tax resolution industry.
Recognized for empowering our team, cultivating growth, and creating a culture of care.
BEAUMONT, TEXAS / ACCESS Newswire / July 3, 2025 / NavSav Insurance is proud to be Certified™ by Great Place To Work®. The prestigious award is based entirely on what current employees say about their experience working at NavSav. This year, 86% of employees said that when you join the company, you are made to feel welcome.
NavSav GPTW
Great Place To Work® is the global authority on workplace culture, employee experience, and the leadership behaviors proven to deliver market-leading revenue, employee retention and increased innovation.
“Great Place To Work Certification is a highly coveted achievement that requires consistent and intentional dedication to the overall employee experience,” says Sarah Lewis-Kulin, the Vice President of Global Recognition at Great Place To Work. She emphasizes that Certification is the official recognition earned by the real-time feedback of employees regarding their company culture. “By successfully earning this recognition, it’s evident that NavSav stands out as one of the top companies to work for, providing a great workplace environment for its employees.”
“We’re incredibly honored to be recognized as a Great Place to Work® in 2025,” said Brent Walters, CEO of NavSav. “This certification is a testament to the daily dedication of our team, whose commitment to innovation and excellence drives everything we do. At NavSav, we believe a positive workplace culture is the cornerstone of outstanding service and sustained success, and this recognition reinforces our ongoing mission to support both our people and our clients.”
According to Great Place To Work research, job seekers are 4.5 times more likely to find a great boss at a Certified great workplace. Additionally, employees at Certified workplaces are 93% more likely to look forward to coming to work, twice as likely to be paid fairly, earn a fair share of the company’s profits and have a fair chance at promotion.
About NavSav Insurance
NavSav Insurance is a family of independent insurance agencies shaking up the insurance industry by saying goodbye to limited products and providing customers high-quality alternatives from higher rates. We’re an innovative company built by industry leaders with decades of experience and success on both sides of the business. We provide our agents and their clients with options to fit their personalized needs. We’ve partnered with over 150+ carriers to ensure remarkable service and coverage. As independent insurance advisers, we work for our customers and deliver an unprecedented insurance experience. We research more coverage and price options than any other company in the market and are able to discover the best protection and value for your needs. Visit us at Navsav.com for more information.
About Great Place to Work Certification™
Great Place To Work® Certification™ is the most definitive “employer-of-choice” recognition that companies aspire to achieve. It’s the only recognition based entirely on what employees report about their workplace experience. This certification is recognized worldwide by employees and employers alike and is the global benchmark for identifying and recognizing outstanding employee experience. Every year, more than 10,000 companies across 60 countries apply to get Great Place To Work-Certified.
ORLANDO, FLORIDA / ACCESS Newswire / July 3, 2025 / RedChip Companies will air interviews with Fathom Holdings, Inc. (Nasdaq:FTHM) and FibroBiologics, Inc. (Nasdaq:FBLG) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, July 5, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
In an exclusive interview, Marco Fregenal, CEO of Fathom Holdings, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the company’s disruptive approach to real estate services through its proprietary, technology-driven platform. Fregenal highlights Fathom’s flat-fee commission model, which empowers agents to retain more of their earnings while enabling industry-leading retention and rapid national expansion. With operations in 43 states and a network of over 14,700 agents, Fathom is scaling efficiently through its virtual model, integrated ancillary services, and strategic acquisitions, including the recent addition of My Home Group. He also addresses Fathom’s innovative Bitcoin strategy and strong financial performance, including a 32% year-over-year revenue increase in Q1 2025, positioning the Company to capture additional market share amid an improving housing market.
Pete O’Heeron, CEO of FibroBiologics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to spotlight the company’s pioneering work in fibroblast-based cell therapies. O’Heeron discusses the advantages of fibroblasts over traditional stem cells, highlighting their regenerative and immunomodulatory properties, scalability, and safety profile. He outlines the Company’s robust pipeline, led by CYWC628 for diabetic foot ulcers, which is slated to enter a Phase 1/2 clinical trial in Australia later this year. Additional programs, including CybroCell™ for degenerative disc disease and CYMS101 for multiple sclerosis, target multi-billion-dollar markets and are supported by promising preclinical and early human data. With over 240 issued and pending patents, a recently completed cGMP-compliant cell bank, and a seasoned leadership team, FibroBiologics is advancing a scalable, off-the-shelf platform poised to transform treatment for chronic diseases and deliver significant long-term value to shareholders.
Fathom Holdings Inc. is a national, technology-driven real estate services platform integrating residential brokerage, mortgage, title, and SaaS offerings to brokerages and agents by leveraging its proprietary cloud-based software, intelliAgent. The Company’s brands include Fathom Realty, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. For more information, visit www.FathomInc.com.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 275+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.
About RedChip Companies
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights.
To learn more about RedChip’s products and services, please visit:
Alembic to expand their U.S. commercial portfolio with FDA-approved PIVYA for the treatment of women with uncomplicated urinary tract infections
PIVYA expected to be available in the U.S. in the 4th quarter of 2025.
LONDON, UK / ACCESS Newswire / July 3, 2025 / UTILITY therapeutics Ltd. (UTILITY), a biotechnology company focused on the development of PIVYA (pivmecillinam 185 mg tablets), a penicillin class antibacterial approved by the U.S. Food and Drug Administration (FDA) for the treatment of uncomplicated urinary tract infection (uUTI), today announced that it has been acquired by Alembic Pharmaceuticals, Inc. (Alembic).
PIVYA marked the first antibiotic in approximately 20 years to earn FDA approval for uUTI, a common bacterial infection that afflicts millions of women annually. The FDA approved PIVYA in April 2024 for use in female patients 18 years of age and older with uUTI caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus. PIVYA has a unique mechanism of action that targets the cell wall of gram-negative bacteria.
Additional U.S. prescribing information about PIVYA can be found at www.pivya.com.
“We are thrilled that Alembic Pharmaceuticals understands the clinical and commercial value of PIVYA and will bring this proven treatment to female patients in need across the U.S.,” said Tom Hadley, President and CEO of UTILITY therapeutics. “With current therapies failing and the armament of uUTI antibiotics perilously thin, PIVYA provides U.S. clinicians with a new and effective treatment option that has a long safety record. We are grateful for the support of our Board of Directors and investors, including the AMR Action Fund, whose collective support was instrumental in helping us obtain FDA approval for PIVYA.”
The UTILITY therapeutics Ltd. Board of Directors and Observers includes:
Alan S. Roemer, MBA, MPH, Chairman of the Board
Morten Sommer, PhD, Co-Founder
Rasmus Toft-Kehler, PhD, Co-Founder
Andrew Davis, Independent Director
Larry Edwards, Independent Director
Thomas Hadley, President & CEO
Henry Skinner, PhD, MJur, MBA, AMR Action Fund
Tero Wennberg, PhD, Observer, LEO Pharma
Henni-Karoliina Ropponen, PhD, Observer, AMR Action Fund
“The acquisition of UTILITY and the commercialization of PIVYA are important steps in Alembic’s strategic goal to provide branded pharmaceutical products to the U.S. healthcare market,” said Craig Salmon, President of Alembic Pharmaceuticals, Inc. “PIVYA will further enhance Alembic’s ability to build long-term value by combining global research, regulatory, and manufacturing strengths with a sharpened focus on specialty segments. Alembic plans to make PIVYA available in the U.S. in the 4th quarter of 2025.”
“I am excited to see Alembic drive the commercialization of PIVYA, which is uniquely positioned to help millions of American women with urinary tract infections,” said Dr. Morten Sommer, Professor of microbiology at the Technical University of Denmark, and co-founder and board member of UTILITY therapeutics. “With a novel mechanism of action, not previously deployed in the U.S., PIVYA can become a cornerstone of the treatment of urinary tract infections based on its first-line positioning in the Infectious Disease Society of America treatment guidelines. On behalf of the co-founders, investors, and Board of Directors, we are excited that PIVYA will help address the societal impact of the uUTI disease burden in women.”
About PIVYA (pivmecillinam oral tablets 185mg)
PIVYA, an oral prodrug of mecillinam, is a penicillin class antibacterial indicated for the treatment of female patients 18 years of age and older with uncomplicated urinary tract infections (uUTI) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus.
Mecillinam demonstrated in vitro activity against Enterobacterales in the presence of some beta-lactamases and extended-spectrum beta-lactamases (ESBL) of the following groups: CTX-M, SHV, TEM, AmpC. The inhibitory action of mecillinam on PBP-2 results in low cross-resistance with certain beta-lactams. The frequency of resistance to mecillinam in E. coli range from 8×10-8 to 2×10-5 when exposed to 32-256 times MIC.
PIVYA has been proven safe and effective in three clinical trials with the most common Adverse Reactions Occurring in ≥1% of Patients Receiving PIVYA (Adjusted for Study Size); Nausea (4.3%), Diarrhea (2.1%), Vulvovaginal candidiasis (1.8%), Genital pruritus (1.8%), and Headache (1.4%).
PIVYA demonstrated strong response in three controlled clinical trials comparing different PIVYA dosing regimens to placebo (Trial 1), to another oral antibacterial drug (Trial 2), or to ibuprofen (Trial 4) evaluated the efficacy of pivmecillinam for the treatment of uUTI. Efficacy was assessed in the Microbiological Intent-to-Treat (micro-ITT) population which included all randomized subjects with a positive baseline urine culture defined as ≥105 colony-forming-units (CFU)/mL of a uropathogen where CFU count was available and no more than 2 species of microorganisms, regardless of colony count, and no baseline pathogen was non-susceptible to the active comparator. The composite response rates (composite endpoint of clinical cure and microbiological response), as well as clinical cure and microbiological response rates of the recommended 185 mg three times daily dosing regimen.
Composite Response Rates (Clinical Cure and Microbiological Response) at TOC in the uUTI trials (Micro ITT Population)
Serious hypersensitivity reactions (e.g., anaphylaxis or Stevens-Johnson syndrome) to PIVYA or to other beta-lactam antibacterial drugs (e.g., penicillins and cephalosporins).
Primary or secondary carnitine deficiency resulting from inherited disorders of mitochondrial fatty acid oxidation and carnitine metabolism such as carnitine transporter defect or other inborn errors of metabolism (e.g., methylmalonic aciduria, or propionic academia).
Acute porphyria.
Warnings and precautions
Hypersensitivity Reactions: Serious hypersensitivity reactions including anaphylaxis have been reported in patients receiving PIVYA. If hypersensitivity reactions occur, discontinue treatment with PIVYA and institute appropriate therapy.
Severe Cutaneous Adverse Reactions (SCAR): Acute Generalized Exanthematous Pustulosis (AGEP), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) have been reported with PIVYA. Monitor closely and discontinue PIVYA at the first signs or symptoms of SCAR or other signs of hypersensitivity.
Carnitine Depletion: In patients at risk for reductions in serum carnitine, e.g., significant renal impairment or decreased muscle mass, consider alternative antibacterial therapies. PIVYA is not recommended when prolonged antibacterial treatment is necessary. Avoid concurrent treatment with valproic acid, valproate or other pivalate-generating drugs due to increased risk of carnitine depletion.
Clostridioides difficile-Associated Diarrhea (CDAD): This has been reported with nearly all systemic antibacterial agents, including PIVYA. Evaluate if diarrhea occurs.
Interference with Newborn Screening Test: Treatment of a pregnant individual with PIVYA prior to delivery may cause a false positive test for isovaleric acidemia in the newborn as part of newborn screening. Prompt follow-up of a positive newborn screening result for isovaleric acidemia is recommended.
About UTILITY therapeutics Ltd.
UTILITY has exclusive U.S. commercial rights to two European-approved antibiotics, pivmecillinam and mecillinam, for the treatment of urinary tract infections (UTI). Pivmecillinam is an oral prodrug of mecillinam that has been approved by the FDA for the treatment of women with uncomplicated urinary tract infections. PIVYA has a unique mechanism of action for infections caused by Gram-negative bacteria, including extended-spectrum beta-lactamases. Mecillinam, an intravenous (IV) formulation, may be developed as a first-line therapy for complicated UTI (cUTI) in the hospital setting.
Demonstrating sustained growth and demand in the Canadian market
MIAMI BEACH, FLORIDA / ACCESS Newswire / July 3, 2025 / LQR House Inc. (the “Company” or “LQR House”) (NASDAQ:YHC), a niche ecommerce platform specializing in the spirits and beverage industry, is pleased to announce that Of The Earth Distribution Corp., an Ontario-based importer of premium craft spirits, has placed its third major purchase order, totaling 176 cases of SWOL Tequila.
The Company believes that this latest order reflects continued momentum across both trade and consumer channels in the Ontario market. The Company also introduced a refreshed 9-bottle case format and an enhanced bottle design, both aimed at increasing shelf visibility and reinforcing the brand’s premium positioning.
The growing volume supports LQR House’s broader expansion strategy into Canada’s hospitality industry. In the past quarter alone, Of The Earth Distribution has onboarded 40 new on-premise accounts, spanning licensed restaurants, bars, and clubs throughout Ontario. At the same time, direct-to-consumer sales have shown steady growth, signaling strong product-market fit and growing brand recognition.
“This new order is both a response to market demand and a signal of where we’re headed as a company,” said Jason Pucci, Founder and CEO of Of The Earth Distribution Corp. “The updated case size supports greater efficiency for our trade partners, while the new bottle design represents a significant step forward in aligning our visual identity with the premium quality of the product inside.”
Sean Dollinger, CEO of LQR House, added “I’ve always said-three is a streak. In a category as saturated and competitive as tequila, where new brands seem to appear daily, we consider this level of repeat demand a clear validation of our strategy and the product’s impact. It’s incredibly rewarding to watch something resonate so strongly in the market, and I believe this momentum is just the beginning of where we’re headed.”
About LQR House Inc.
LQR House intends to become a prominent force in the wine and spirits e-commerce sector, epitomized by its flagship alcohol marketplace, cwspirits.com. This platform seamlessly delivers a diverse range of emerging, premium, and luxury spirits, wines, and champagnes from esteemed retail partners like Country Wine & Spirits. Functioning as a technology-driven hub, LQR House utilizes software, data analytics, and artificial intelligence to elevate consumer experience. CWSpirits.com stands out as the go-to destination for modern, convenience-oriented shoppers, providing a curated selection of alcohol products delivered to homes across the United States. Beyond its role in an e-commerce sector, LQR House is a marketing agency with a specialized focus on the alcohol industry. The Company measures campaign success by directly correlating it with sales on CWSpirits.com, demonstrating a return on investment. Backed by an influential network of around 460 figures in the alcohol space, LQR House strategically drives traffic to CWSpirits.com, enhancing brand visibility. LQR House intends to disrupt the traditional landscape of the alcohol industry, driven by its dedication to providing an unparalleled online purchasing experience and delivering tailored marketing solutions.
About Of The Earth Distribution Corp.
Of The Earth Distribution Corp. is a premier distributor of fine spirits in Canada, committed to delivering top-quality products to the Canadian market. With a focus on exceptional service and client satisfaction, the company works with global partners to bring world-class spirits to Ontario and beyond. The company is licensed through the LCBO and operates as a boutique importer focused on culturally rooted, sustainably produced spirits. The company is committed to working directly with heritage producers and delivering premium products to both the hospitality trade and discerning consumers across Ontario.
Forward-Looking Statements
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Shareholders can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “potential,” “continue” or other similar expressions. Forward-looking statements contained in this press release are made only as of the date of this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations that arise after the date hereof, except as may be required by law. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions, and other factors discussed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in other reports and documents that the Company files from time to time with the United States Securities and Exchange Commission (the “SEC”). You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the headings “Risk Factors”. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in other reports and documents that the Company files from time to time with the SEC. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. References and links to websites have been provided as a convenience, and the information contained on such websites has not been incorporated by reference into this press release.
HOUSTON, TX / ACCESS Newswire / July 3, 2025 / Envirotech Vehicles, Inc. (NASDAQ:EVTV) (“Envirotech,” “EVT”, or the “Company”) is pleased to announce the completed delivery of another EVT Bumble Bee electric school bus to Texas independent school districts. The bus was delivered this week to the Kopperl Independent School District (“Kopperl ISD”) in Kopperl, Texas.
Under the U.S. Environmental Protection Agency’s Clean School Bus (“CSB”) Program-which was established to provide $5 billion over five years to replace existing fleets with zero-emission buses- $8,570,000 was awarded to cover the production and distribution of 25 electric school buses by Envirotech to school districts in Texas and Arkansas.
“We have now completed four bus deliveries in the past 15 days and expect to see growth in this segment continue to ramp up,” remarked Jason Maddox, President and Interim Chief Financial Officer of Envirotech. “We express great thanks to the EPA for the Clean School Bus Program and look forward to additional school bus deliveries this year as well as the opportunity to potentially access additional grant funding to further expand this vertical in 2026.”
The EVT Bumble Bee fast-charging 100% electric school bus has a proven range of up to 150 miles on a single charge with zero emissions and no noise pollution. It represents a significant improvement over conventional fossil fuel powered buses:
Zero tailpipe emissions-students, drivers, and members of the community will be exposed to significantly less harmful diesel emissions like particulate matter and nitrogen oxides.
Reduced greenhouse gas emissions compared to diesel school buses.
Reduced maintenance costs due to regenerative braking and no engine or exhaust system.
Potential for reduced fuel costs compared to diesel depending on electricity costs.
Quiet, clean operation.
Kopperl ISD Superintendent Katrina Adcock was present when Envirotech delivered the Bumble Bee electric school bus to the district. “The bus was delivered this morning. It is super cool! Exciting times for Kopperl ISD and Bosque County.”
Business owners and potential strategic partners interested in learning about Envirotech’s technology offering are invited to visit the Company’s website and can contact the Company through the website at https://evtvusa.com/contact-evtv/.
About Envirotech Vehicles Envirotech Vehicles, Inc. (NASDAQ:EVTV) is a technology company dedicated to revolutionizing the electric vehicle landscape by designing and manufacturing electric commercial vehicles that offer sustainable, efficient, and cost-effective transportation solutions. Committed to driving the future of mobility, Envirotech is pushing the boundaries of innovation and sustainability.
Cautionary Statement Regarding Forward-Looking Statements Statements made in this press release that relate to future plans, events, financial results, prospects, or performance are forward-looking statements and include, but are not limited to, statements regarding the proposed delivery of additional EVT electric school buses, future grants under the CSB Program towards EVT electric school buses, and the intended benefits and performance of EVT electric school buses. While they are based on the current expectations and assumptions and beliefs of management, such forward-looking statements are subject to a number of risks, uncertainties, assumptions, and other factors that could cause actual results to differ materially from the expectations expressed in this press release. Important factors that could cause actual results to differ materially from current expectations include, among others, Envirotech’s ability to successfully deliver electric vehicles, Envirotech’s ability to maintain compliance with The Nasdaq Stock Market LLC listing requirements, and the other risks and uncertainties disclosed in reports filed by Envirotech with the Securities and Exchange Commission, all of which are available online at www.sec.gov. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words “will,” “estimated,” “planned,” “expected,” “believes,” “strategy,” “opportunity,” “anticipated,” “outlook,” “designed,” and similar words. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, Envirotech undertakes no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances, or unanticipated events.
